Citation: | Huang Changming, Zheng Hualong, Wang Fuhai, et al. Progress of research and technical in minimally invasive surgery for gastric cancer[J]. Chinese Journal of Digestive Surgery, 2023, 22(1): 65-69. DOI: 10.3760/cma.j.cn115610-20221115-00692 |
Gastric cancer is one of the most common malignant tumors in the world, and its incidence and mortality are among the top of malignant tumors in China. Since Kitano et al com-plete the first laparoscopic radical gastrectomy for gastric cancer in the world in 1992, the laparos-copic technology has developed rapidly. After more than 30 years of exploration and practice, the clinical diagnosis and treatment of gastric cancer in China has also made considerable progress. A large number of clinical studies at home and abroad have confirmed that laparoscopic radical gas-trectomy is no less effective than traditional open surgery in the short and long term. Laparoscopic radical gastrectomy has the characteristics of less trauma, faster recovery of gastrointestinal func-tion, less postoperative pain, and shorter average hospital stay. It has gradually replaced open surgery as the mainstream surgical method for gastric cancer. As the concept of surgical treatment for gastric cancer continues to update, emerging minimally invasive technologies continue to emerge, including robotic surgery systems and indocyanine green tracing technology, which are increasingly used in gastric cancer surgery, making gastric cancer surgery more minimally invasive and accurate, the quality of perigastric lymph node dissection and the domestic gastric cancer surgery technology further improving. Based on the relevant research at home and abroad, the authors review and summarize the latest progress in recent years with the topic of minimally invasive surgery for gastric cancer, aiming to systematically describe the current situation and future prospects of gastric cancer surgery. It is believed that in the future, the clinical diagnosis and treatment of gastric cancer in China will be more standardized, minimally invasive and accurate, more high-quality multicenter clinical research will be carry out and the diagnosis and treatment of gastric cancer will be further improved in China.
[1] |
CaoW, ChenHD, YuYW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl),2021,134(7):783-791. DOI: 10.1097/CM9.0000000000001474.
|
[2] |
陈豪,余佩武,黄昌明,等.腹腔镜远端胃癌D2根治术治疗局部进展期胃癌10年预后及影响因素分析:基于CLASS队列的全国多中心研究[J].中华消化外科杂志,2022,21(3):362-374. DOI: 10.3760/cma.j.cn115610-20220221-00100.
|
[3] |
HuY, HuangC, SunY, et al. Morbidity and mortality of laparoscopic versus open D2 distal gastrectomy for advan-ced gastric cancer: a randomized controlled trial[J]. J Clin Oncol,2016,34(12):1350-1357. DOI:10.1200/JCO.2015. 63.7215.
|
[4] |
YuJ, HuangC, SunY, et al. Effect of laparoscopic vs open distal gastrectomy on 3-year disease-free survival in pati-ents with locally advanced gastric cancer: the CLASS-01 randomized clinical trial [J]. JAMA,2019,321(20):1983-1992. DOI: 10.1001/jama.2019.5359.
|
[5] |
HuangC, LiuH, HuY, et al. Laparoscopic vs open distal gastrectomy for locally advanced gastric cancer: five-year outcomes from the CLASS-01 randomized clinical trial[J]. JAMA Surg,2022,157(1):9-17. DOI:10.1001/jamasurg. 2021.5104.
|
[6] |
LiuF, HuangC, XuZ, et al. Morbidity and mortality of laparoscopic vs open total gastrectomy for clinical stage Ⅰ gastric cancer: the CLASS02 multicenter randomized clinical trial[J]. JAMA Oncol,2020,6(10):1590-1597. DOI:10.10 01/jamaoncol.2020.3152.
|
[7] |
KimW, KimHH, HanSU, et al. Decreased morbidity of laparoscopic distal gastrectomy compared with open distal gastrectomy for stage i gastric cancer: short-term outcomes from a multicenter randomized controlled trial (KLASS-01)[J]. Ann Surg,2016,263(1):28-35. DOI:10.10 97/SLA.0000000000001346.
|
[8] |
KataiHitoshi,MizusawaJunki,KatayamaHiroshi, et al. Short-term surgical outcomes from a phase Ⅲ study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage ⅠA/ⅠB gastric cancer: Japan Clinical Oncology Group Study JCOG0912[J]. Gastric Cancer,2017,20(4):699-708. DOI: 10.1007/s10120-016-0646-9.
|
[9] |
KimHH, HanSU, KimMC, et al. Effect of laparoscopic distal gastrectomy vs open distal gastrectomy on long-term survival among patients with stage Ⅰ gastric cancer: the KLASS-01 randomized clinical trial[J]. JAMA Oncol,2019,5(4):506-513. DOI: 10.1001/jamaoncol.2018.6727.
|
[10] |
KataiH, MizusawaJ, KatayamaH, et al. Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage ⅠA or ⅠB gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial[J]. Lancet Gastroenterol Hepatol,2020,5(2):142-151. DOI: 10.1016/S2468-1253(19)30332-2.
|
[11] |
LeeHJ, HyungWJ, YangHK, et al. Short-term outcomes of a multicenter randomized controlled trial comparing laparoscopic distal gastrectomy with D2 lymphadenectomy to open distal gastrectomy for locally advanced gastric cancer (KLASS-02-RCT)[J]. Ann Surg,2019,270(6):983-991. DOI: 10.1097/SLA.0000000000003217.
|
[12] |
HyungWJ, YangHK, ParkYK, et al. Long-term outcomes of laparoscopic distal gastrectomy for locally advanced gastric cancer: the KLASS-02-RCT randomized clinical trial[J]. J Clin Oncol,2020,38(28):3304-3313. DOI: 10.1200/JCO.20.01210.
|
[13] |
LiZ, ShanF, YingX, et al. Assessment of laparoscopic distal gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: a randomized clinical trial[J]. JAMA Surg,2019,154(12):1093-1101. DOI:10.1001/jama surg.2019.3473.
|
[14] |
HashizumeM, SugimachiK. Robot-assisted gastric surgery[J]. Surg Clin North Am,2003,83(6):1429-1444. DOI: 10.1016/S0039-6109(03)00158-0.
|
[15] |
LuJ, ZhengCH, XuBB, et al. Assessment of robotic versus laparoscopic distal gastrectomy for gastric cancer: a randomized controlled trial[J]. Ann Surg,2021,273(5):858-867. DOI: 10.1097/SLA.0000000000004466.
|
[16] |
ChenQY, ZhongQ, LiuZY, et al. Surgical outcomes, technical performance, and surgery burden of robotic total gastrectomy for locally advanced gastric cancer: a prospective study[J]. Ann Surg,2022,276(5):e434-e443. DOI:10. 1097/SLA.0000000000004764.
|
[17] |
LiZY, ZhouYB, LiTY, et al. Robotic Gastrectomy versus laparoscopic gastrectomy for gastric cancer: a multicenter cohort study of 5 402 patients in China[J]. Ann Surg,2021[2023-01-05]. https://pubmed.ncbi.nlm.nih.gov/34225299. DOI:10.1097/SLA.0000000000005046. [Published online ahead of print].
|
[18] |
OjimaT, NakamuraM, HayataK, et al. Short-term outcomes of robotic gastrectomy vs laparoscopic gastrectomy for patients with gastric cancer: a randomized clinical trial[J]. JAMA Surg,2021,156(10):954-963. DOI: 10.1001/jamasurg.2021.3182.
|
[19] |
马云涛,卢婷婷,马世勋,等.《中国机器人胃癌手术指南》解读[J/CD].中华腔镜外科杂志:电子版,2021,14(4):193-200. DOI: 10.3877/cma.j.issn.1674-6899.2021.04.001.
|
[20] |
Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4)[J]. Gastric Cancer,2017 ,20(1):1-19. DOI: 10.1007/s10120-016-0622-4.
|
[21] |
AjaniJA, D'AmicoTA, BentremDJ,et al. Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw,2019,17(7):855-883. DOI:10.6004/jnccn.2019. 0033.
|
[22] |
VahrmeijerAL, HuttemanM, van der VorstJR, et al. Image-guided cancer surgery using near-infrared fluorescence[J]. Nat Rev Clin Oncol,2013,10(9):507-518. DOI: 10.1038/nrclinonc.2013.123.
|
[23] |
ValenteSA, Al-HilliZ, RadfordDM, et al. Near infrared fluorescent lymph node mapping with indocyanine green in breast cancer patients: a prospective trial[J]. J Am Coll Surg,2019,228(4):672-678. DOI:10.1016/j.jamcollsurg. 2018.12.001.
|
[24] |
YamashitaS, TokuishiK, AnamiK, et al. Video-assisted thoracoscopic indocyanine green fluorescence imaging sys-tem shows sentinel lymph nodes in non-small-cell lung cancer[J]. J Thorac Cardiovasc Surg,2011,141(1):141-144. DOI: 10.1016/j.jtcvs.2010.01.028.
|
[25] |
BrouwerOR, KlopWM, BuckleT, et al. Feasibility of sentinel node biopsy in head and neck melanoma using a hybrid radioactive and fluorescent tracer[J]. Ann Surg Oncol,2012,19(6):1988-1994. DOI: 10.1245/s10434-011-2180-7.
|
[26] |
TajimaY, YamazakiK, MasudaY, et al. Sentinel node mapping guided by indocyanine green fluorescence imaging in gastric cancer[J]. Ann Surg,2009,249(1):58-62. DOI: 10.1097/SLA.0b013e3181927267.
|
[27] |
ChenQY, XieJW, ZhongQ, et al. Safety and efficacy of indocyanine green tracer-guided lymph node dissection during laparoscopic radical gastrectomy in patients with gastric cancer: a randomized clinical trial[J]. JAMA Surg,2020,155(4):300-311. DOI: 10.1001/jamasurg.2019.6033.
|
[28] |
ChenQY, ZhongQ, LiP, et al. Comparison of submucosal and subserosal approaches toward optimized indocyanine green tracer-guided laparoscopic lymphadenectomy for patients with gastric cancer (FUGES-019): a randomized controlled trial[J]. BMC Med,2021,19(1):276. DOI:10.11 86/s12916-021-02125-y.
|
[29] |
Japanese gastric cancer treatment guidelines 2018 (5th edition)[J]. Gastric Cancer,2021,24(1):1-21. DOI: 10.1007/s10120-020-01042-y.
|
[30] |
中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会(CSCO)胃癌诊疗指南2021[M].北京:人民卫生出版社,2021.
|
[31] |
SasadaS, NinomiyaM, NishizakiM, et al. Frequency of lymph node metastasis to the splenic hilus and effect of splenectomy in proximal gastric cancer[J]. Anticancer Res,2009,29(8):3347-3351.
|
[32] |
IkeguchiM, KaibaraN. Lymph node metastasis at the splenic hilum in proximal gastric cancer[J]. Am Surg,2004,70(7):645-648.
|
[33] |
MaranoL, RondelliF, BartoliA, et al. Oncologic effectiveness and safety of splenectomy in total gastrectomy for proximal gastric carcinoma: meta-analysis of randomized controlled trials[J]. Anticancer Res,2018,38(6):3609-3617. DOI: 10.21873/anticanres.12635.
|
[34] |
SanoT, SasakoM, MizusawaJ, et al. Randomized contro-lled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma[J]. Ann Surg,2017,265(2):277-283. DOI: 10.1097/SLA.0000000000001814.
|
[35] |
HuangCM, ChenQY, LinJX, et al. Huang's three- step man-euver for laparoscopic spleen-preserving No.10 lymph node dissection for advanced proximal gastric cancer[J]. Chin J Cancer Res,2014,26(2):208-210. DOI: 10.3978/j.issn.1000-9604.2014.04.05.
|
[36] |
ZhengC, XuY, ZhaoG, et al. Outcomes of laparoscopic total gastrectomy combined with spleen-preserving hilar lymphadenectomy for locally advanced proximal gastric cancer: a nonrandomized clinical trial[J]. JAMA Netw Open,2021,4(12):e2139992. DOI:10.1001/jamanetworkopen. 2021.39992.
|
[37] |
ZhengCH, XuYC, ZhaoG, et al. Safety and feasibility of laparoscopic spleen-preserving No.10 lymph node dissection for locally advanced upper third gastric cancer: a prospective, multicenter clinical trial[J]. Surg Endosc,2020,34(11):5062-5073. DOI: 10.1007/s00464-019-07306-8.
|
[38] |
KinoshitaT, SatoR, AkimotoE, et al. Can laparoscopic spleen-preserving splenic hilar lymph node dissection replace prophylactic splenectomy for proximal advanced gastric cancers that invade the greater curvature?[J]. Eur J Surg Oncol,2021,47(6):1466-1472. DOI:10.1016/j.ejso. 2020.11.133.
|
[39] |
LinJX, LinJP, WangZK, et al. Assessment of laparoscopic spleen-preserving hilar lymphadenectomy for advanced proximal gastric cancer without invasion into the greater curvature: a randomized clinical trial[J]. JAMA Surg,2022[2023-01-05]. https://pubmed.ncbi.nlm.nih.gov/36383362/. DOI:10.1001/jamasurg.2022.5307. [published online ahead of print].
|